Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients

Publish date:: October 27, 2020

Key clinical point: Next-generation sequencing revealed therapeutically actionable molecular alterations in patients with relapsed/refractory cancers.

Major finding: In all, 37.6% of patients had actionable alterations, and 17.8% were assigned to targeted treatment.

Study details: The phase 2 NCI-MATCH trial included 5,954 cancer patients from 1,117 sites.

Disclosures: NCI-MATCH was funded by the National Cancer Institute. The authors disclosed relationships with many companies.

Citation:

Flaherty KT et al. J Clin Oncol. 2020 Oct 13. doi: 10.1200/JCO.19.03010.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,